TKIs such as sorafenib and regorafenib primarily target activated pathways in the proliferation class, likely benefiting from blocking cell proliferation by inhibiting the RAF/MEK/ERK signaling pathway and tumor angiogenesis by inhibiting the VEGF and platelet-derived growth factor receptors [8]. Here, MAP2K7 is linked to neoplasm.